TABLE 5.
Summary of Studies Assessing Prognostic Value of Baseline Assessment a
| Assessment | ||||
|---|---|---|---|---|
| Lead Author (Year) | Risk of Bias b | N | Clinical | MRI |
| A Hamid (2014) 1 | Low | 28 | X | |
| A Hamid (2013) 2 | 10 (16) | 360 | X | |
| Askling (2006) 5 | 12 (16) | 33 | X | |
| Askling (2007) 6 | 14 (16) | 15 | X | X |
| Askling (2007) 7 | 14 (16) | 18 | X | X |
| Askling (2008) 8 | 11 (16) | 30 | X | X |
| Askling (2014) 9 | Some concerns | 56 | X | X |
| Askling (2013) 10 | Some concerns | 75 | X | X |
| Cohen (2011) 24 | 14 (16) | 38 | X | |
| Comin (2013) 25 | 20 (24) | 62 | X | |
| Crema (2018) 27 | 11 (16) | 22 | X | |
| Ekstrand (2012) 29 | 12 (16) | 207 | X | |
| Ekstrand (2016) 30 | 12 (16) | 255 | X | |
| Gibbs (2004) 33 | 12 (16) | 31 | X | |
| Guillodo (2014) 36 | 12 (16) | 128 | X | |
| Hallen (2014) 37 | 13 (16) | 386 | X | |
| Hamilton (2018) 40 | 13 (16) | 110 | X | |
| Jacobsen (2016) 44 | 14 (16) | 90 | X | X |
| Kilcoyne (2011) 45 | 10 (16) | 48 | X | |
| Malliaropoulos (2010) 55 | 21 (24) | 165 | X | |
| Moen (2014) 59 | 13 (16) | 74 | X | X |
| Pollock (2016) 63 | 11 (16) | 44 | X | |
| Pomeranz (1993) 64 | 10 (16) | 14 | X | |
| Schneider-Kolsky (2006) 69 | 21 (24) | 58 | X | X |
| Silder (2013) 76 | Low | 25 | X | |
| Slavotinek (2002) 75 | 12 (16) | 30 | X | |
| van der Made (2018) 80 | 14 (16) | 70 | X | |
| Verrall (2003) 81 | 12 (16) | 83 | X | X |
| Wangensteen (2015) 82 | 11 (16) | 180 | X | X |
| Warren (2010) 83 | 13 (16) | 59 | X | |
a MRI, magnetic resonance imaging; X, outcome(s) reported.
b Reported as Methodological Index for Non-Randomized Studies score (maximum score) for nonrandomized studies or Cochrane Risk-of-Bias Tool for Randomized Trials.